Autus Valve Pivotal Study (NCT05006404)
Autus Size-Adjustable Valve for Surgical Pulmonary Valve Replacement Pivotal Study
π©Ί Plain-English Summary (8th-Grade Level)
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years. The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.
Who can join: Review the eligibility criteria below.
Location: Children's Hospital Los Angeles β Los Angeles, California
Age range: 18 Months to 16 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (12 Sites)
- Children's Hospital Los Angeles β Los Angeles, California
- Children's Hospital Colorado β Aurora, Colorado
- Children's Healthcare of Atlanta β Atlanta, Georgia
- Ann and Robert H. Lurie Children's Hospital of Chicago β Chicago, Illinois
- Boston Children's Hospital β Boston, Massachusetts
- University of Michigan - Mott Children's Hospital β Ann Arbor, Michigan
- Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital β New York, New York
- Duke University β Durham, North Carolina
- Nationwide Children's Hospital β Columbus, Ohio
- Children's Hospital of Philadelphia β Philadelphia, Pennsylvania
- University of Utah - Intermountain Primary Children's Hospital β Salt Lake City, Utah
- Seattle Children's Hospital β Seattle, Washington
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Congenital Heart Disease
- Technical Development for Pediatric Cardiovascular MRI β Washington D.C., District of Columbia
- Harmony TPV Post-Approval Study β Birmingham, Alabama
- The Medtronic Harmonyβ’ Transcatheter Pulmonary Valve Clinical Study β Los Angeles, California
- Peer Coaching Intervention in Young Adults With Congenital Heart Disease β Durham, North Carolina
- SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure β Toronto, Ontario
Explore by condition: All Congenital Heart Disease clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.